MARINOMED BIOTECH AG: CARRAGELOSE® EFFECTIVE AGAINST SARS-CoV-2 IN CELL CULTURE ASSAYS
Marinomed Biotech AG announces that pre-clinical data show that Carragelose® has the potential to reduce the risk of an infection with SARS-CoV-2 and may also treat COVID-19.
Data from Marinomed’s cell-culture study confirm that Carragelose® works in a dose-dependent manner to strongly reduce the infection of cells from the SARS-CoV-2 virus.
Carragelose® coats the mucosal tissues of the respiratory tract susceptible to attack from SARS-CoV-2, forming a physical barrier that helps to protect against viral infection and viral spread. This in turn may suppress the viral load and the body’s own natural defences may fight the virus more efficiently.
Typically, people can become ill with COVID-19 after the SARS-CoV-2 virus has entered the body through the nose or throat.
These studies results enable Marinomed to build on the data that have been already collected from clinical trials with other viruses, and these results can be extrapolated that SARS-CoV-2 virus may be neutralised as well.
The effectiveness of Carragelose® has been proven in clinical trials with more than 600 patients suffering from early symptoms of the common cold. A particular advantage of Carragelose® is the broad activity of the polymer against different virus strains, such as Rhinovirus and already known Coronaviruses. In addition, the safety profile of Carragelose® is very good.
These pre-clinical data underscore the protection Carragelose® can provide against SARS-CoV-2 and a multitude of different respiratory viruses. This will be particularly important as Marinomed continues to deal with COVID-19 and moves into this year’s cold and flu season.
As a next step, Marinomed is now planning clinical tests using the same technology for an inhalation solution that could also work in the lungs. The trials will include patients with a risk of virally induced pneumonia, a main complication of COVID-19 and other viruses, such as Influenza A. The first efficacy results are expected within the next 12 months. If the clinical data are positive, an inhalation product with Carragelose® could be available in 2021.
Products containing Carragelose®, such as nasal sprays, lozenges or a throat spray have been marketed in Austria since 2008. By now, the products have been established as first causative treatment of common cold and flu-like diseases world-wide and are distributed in more than 40 countries.
About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna (Austria) and listed on the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on patent-protected technology platforms in the field of respiratory and ophthalmological diseases. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Further information is available at: https://smex12-5-en-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=www.marinomed.com&umid=cf4716e7-542d-4aa3-aa7e-dfdfa2be1a08&auth=374692e779bef9bacadb890be4a9a6f4a7496c7c-42464819ffb4480aa4da934ddde7fca95598a387.
For further enquiries please contact:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Hovengasse 25, 2100 Korneuburg, Austria
T +43 2262 90300
E-Mail: eva.prieschl@marinomed.com
Eva Ruppnig
Senior Consultant, Metrum Communications
Buernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 335
E-Mail: e.ruppnig@metrum.at